Browsing by Author "Özgür, G"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey
    Soyer, N; Ali, R; Turgut, M; Haznedaroglu, IC; Yilmaz, F; Aydogdu, I; Pir, A; Karakus, V; Özgür, G; Kis, C; Ceran, F; Ilhan, G; Özkan, M; Aslaner, M; Ince, I; Yavasoglu, I; Gediz, F; Sönmez, M; Güvenç, B; Özet, G; Kaya, E; Vural, F; Sahin, F; Töbü, M; Durusoy, R; Saydam, G
    Background/aim: The aim of this study is to assess the efficacy and safety of ruxolitinib in patients with myelofibrosis. Materials and methods: From 15 centers, 176 patients (53.4% male, 46.6% female) were retrospectively evaluated. Results: The median age at ruxolitinib initiation was 62 (28-87) and 100 (56.8%) of all were diagnosed as PMF. Constitutional symptoms were observed in 84.7%. The median initiation dose of ruxolitinib was 30 mg (10-40). Dose change was made in 69 (39.2%) patients. Forty seven (35.6%) and 20 (15.2%) of 132 patients had hematological and nonhematological adverse events, respectively. The mean spleen sizes before and after ruxolitinib treatment were 219.67 +/- 46.79 mm versus 199.49 +/- 40.95 mm, respectively (p < 0.001). There was no correlation between baseline features and subsequent spleen response. Overall survival at 1-year was 89.5% and the median follow up was 10 (1-55) months. We could not show any relationship between survival and reduction in spleen size (p = 0.73). Conclusion: We found ruxolitinib to be safe, well tolerated, and effective in real-life clinical practice in Turkey. Ruxolitinib dose titration can provide better responses in terms of not only clinical benefit but also for long term of ruxolitinib treatment.
  • No Thumbnail Available
    Item
    Current practice of autologous hematopoietic progenitor cell mobilization in adult patients with multiple myeloma and lymphoma: The results of a survey from Turkish hematology research and education group (ThREG)
    Tekgündüz, E; Demirkan, F; Vural, F; Göker, H; Özdogu, H; Kiki, I; Aydogdu, I; Kaynar, L; Erkurt, MA; Çagirgan, S; Besisik, S; Dagdas, S; Koca, E; Kadiköylu, G; Gündüz, E; Yilmaz, M; Beköz, H; Ural, AU; Bastürk, A; Arat, M; Albayrak, M; Öztürk, E; Akyol, A; Bolaman, AZ; Nevruz, O; Özkan, HA; Özgür, G; Altuntas, F
    Autologous hematopoietic cell transplantation (AHCT) is an established treatment option for adult patients presenting with multiple myeloma (MM), Hodgkin lymphoma (HL) and various subtypes of non-Hodgkin lymphoma (NHL) in upfront and/or relapsed/refractory disease settings. Although there are recently published consensus guidelines addressing critical issues regarding autologous hematopoietic progenitor cell mobilization (HPCM), mobilization strategies of transplant centers show high variability in terms of routine practice. In order to understand the current institutional policies regarding HPCM in Turkey and to obtain the required basic data for preparation of a national positional statement on this issue, Turkish Hematology Research and Education Group (ThREG) conducted a web-based HPCM survey. The survey was designed to include multiple-choice questions regarding institutional practice of HPCM in adults presenting MM, HL, and NHL. The representatives of 27 adult HCT centers participated to the study. Here we report the results of this survey shedding light on the real world experience in Turkey in terms of autologous HPCM mobilization strategies in patients presenting with MM and lymphoma. (C) 2017 Elsevier Ltd. All rights reserved.